CIK 0001600620 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 283.1 M | 134.0 M | ||
| Net income (USD) | -102.7 M | -88.4 M | ||
| Diluted EPS (USD/shares) | 2.07 | -0.76 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-11 | 4 | FORM 4 | 2026-09-10 |
| 2026-08-26 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-08-25 | 4 | FORM 4 | 2026-08-21 |
| 2026-08-21 | 144 | 144 | |
| 2026-08-19 | 8-K | 8-K items 8.01 | 2026-08-19 |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-06 | 8-K | 8-K items 2.02,9.01 | 2026-08-06 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-04 |
| 2026-06-05 | 144 | 144 | |
| 2026-06-04 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-06-04 | 8-K | 8-K items 5.07,9.01 | 2026-06-03 |
| 2026-06-04 | 144 | 144 | |
| 2026-06-02 | 4 | 4 | 2026-05-29 |
| 2026-06-02 | 144 | 144 | |
| 2026-05-20 | 4 | FORM 4 | 2026-05-18 |
| 2026-05-20 | 4 | FORM 4 | 2026-05-18 |
| 2026-05-20 | 4 | FORM 4 | 2026-05-18 |
| 2026-05-11 | 144 | 144 | |
| 2026-05-11 | 144 | 144 | |
| 2026-05-11 | 144 | 144 | |
| 2026-05-11 | 8-K | 8-K items 2.01,9.01 | 2026-05-08 |
| 2026-05-11 | SC TO-T/A | SC TO-T/A |
Forms on file (last 1,000): 6-K 204, 4 150, 8-K 55, 3 29, SC 13D/A 20, 10-Q 17, SUPPL 16, SC 13G 15. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=AUPH (0.002 USD), /gw/filings/filings?ticker=AUPH&form=8-K, /gw/filings/facts?ticker=AUPH&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange